peptide science retatrutide | Research Peptide Vial Triple Agonist Peptides Explained: Retatrutide,

2012;303:F96371

Millions of members who had relied on medications like Wegovy, Zepbound, and Saxenda woke up to letters explaining that their weight loss medications would no longer be covered as of January 1, 2026

The study also linked higher obesity rates to greater income inequality, limited access to healthy foods and higher racial and ethnic segregation

This is prescription medicine tested to the highest regulatory standard versus unregulated supplement stickers

Dungan & DeSantis, 2026)

In 2021, the FDA approved Novo Nordisk's Wegovy, a slight reformulation of Ozempic designed specifically for weight loss, which drove a huge spike in public awareness of GLP-1 agonists